| Literature DB >> 27391332 |
Sofía Sánchez-Iglesias1, Alexander Unruh-Pinheiro1, Cristina Guillín-Amarelle1, Blanca González-Méndez1, Alejandro Ruiz-Riquelme1, Blanca Leticia Rodríguez-Cañete1, Silvia Rodríguez-García1, Encarnación Guillén-Navarro2, Rosario Domingo-Jiménez3, David Araújo-Vilar1.
Abstract
OBJECTIVE: PELD (Progressive Encephalopathy with or without Lipodystrophy or Celia's Encephalopathy) is a fatal and rare neurodegenerative syndrome associated with the BSCL2 mutation c.985C>T, that results in an aberrant transcript without the exon 7 (Celia seipin). The aim of this study was to evaluate both the process of cellular senescence and the effect of unsaturated fatty acids on preadipocytes from a homozygous c.985C>T patient. Also, the role of aberrant seipin isoform on adipogenesis was studied in adipose-derived human mesenchymal stem cells.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27391332 PMCID: PMC4938205 DOI: 10.1371/journal.pone.0158874
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Amplification results of the splicing region.
Results of the amplification of the 573 bp region of cDNA from preadipocytes from the index case and control subject in different passages without Intralipid treatment (a) or in the presence of Intralipid (b). Only samples from the index case show the presence of the 431 base pair-long additional band which once sequenced confirmed the skipping of exon 7.
Relative expression of BSCL2 transcripts.
| With exon 7 | Without exon 7 | With exon 7 | Without exon 7 | |
| 1.034±0.275 | 0.012±0.004 | 0.136±0.035 | 0.120±0.026 | |
| 1.036±0.302 | 0.017±0.005 | 0.164±0.028 | 0.282±0.062 | |
| 1.109±0.321 | 0.016±0.006 | 0.172±0.051 | 0.195±0.059 | |
| With exon 7 | Without exon 7 | With exon 7 | Without exon 7 | |
| 1.096±0.214 | 0.013±0.002 | 0.101±0.017 | 0.079±0.011 | |
| 1.412±0.291 | 0.012±0.002 | 0.142±0.030 | 0.102±0.029 | |
| 1.286±0.236 | 0.010±0.002 | 0.205±0.036 | 0.103±0.020 | |
Relative expression of BSCL2 transcripts referred to BSCL2 transcripts with exon 7 in control (A) at basal conditions, and (B) after Intralipid treatment: skipped transcript referred to BSCL2 transcripts containing the exon 7 in control
*: P<0.05; skipped transcript referred to BSCL2 transcripts containing the exon 7 in index case
#: P<0.05; transcripts with exon 7 in index case referred to BSCL2 transcripts containing the exon 7 in control
§: P<0.05; skipped transcript in index case referred to BSCL2 skipped transcript in control
†: P<0.05
‡: P<0.05 vs. P8. P: passage. All samples were analyzed in duplicate, n = 4. Results were normalized for the RNA polymerase II gene.
Fig 2Relative expression and percentage of change in expression of BSCL2 transcripts after Intralipid treatment.
(a) Percentage of change referred to the relative expression of BSCL2 transcripts with exon 7 and (b) without exon 7, in WT and index case preadipocytes, normalized to the RNA polymerase II gene. White bar: WT; black bar: index case. All samples were analyzed in duplicate, n = 4, *:P<0.05.
Fig 3Representative photographs of SA-β-gal activity in preadipocytes.
Early and late passages preadipocytes of control (WT) and index case (c.985C>T) were subjected to in situ SA-β-gal staining at pH 6 and examined by bright field microscopy. The nuclei were counterstained with Hoechst 33258. Senescent and total cells were quantified in triplicate with ImageJ software, taking 4 random non-overlapping fields of view for each sample. Original magnification ×10.
Fig 4Percentage of change in expression of BSCL2 transcripts and adipogenic genes.
Percentage of change in expression of BSCL2 transcripts and adipogenic genes referred to day 0, (a) BSCL2 with exon 7 (b) BSCL2 without exon 7 (c) PPARG, (d) LPIN1, (e) LPL, in ADSCs (differentiated over 14 days into adipocytes) normalized to the 18S gene. All samples were analyzed in duplicate, n = 4, *:P<0.05.